Retractable Technologies is cutting 16% of its workforce to save $2.2 million annually and strengthen domestic production.

LITTLE ELM, Texas, March 27, 2026--(BUSINESS WIRE)--Retractable Technologies, Inc. ("Retractable") (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of ...

Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2025. Further details concerning the results of operations as well as ...

A recent study published in the Journal of the American Medical Association found that short-term vasopressor use via peripheral IV (PIV) catheters is associated with low adverse event rates, ...

Introduction Ultrasound-guided peripheral cannulation by specialised nurses is increasingly used to improve first-stick success rates in patients with difficult intravenous access (DIVA). Long ...

It’s a common practice — maintaining peripheral intravenous catheters (PIVCs) in stable hospital patients even after the need for IV therapy has been resolved. And the thinking goes, why not? After ...

The global Peripheral Intravenous Catheter (PIVC) market is poised for substantial growth, with an estimated value of USD 7.0 billion in 2025, expected to double to USD 13.9 billion by 2035. This ...

Consistent Trophoblast Cell Surface Antigen 2 Positivity in Tracheobronchial Adenoid Cystic Carcinoma: Expanding Antibody-Drug Conjugate Opportunities in Rare Thoracic Tumor We sought to evaluate PBSC ...

On September 15, 2025, Johnson & Johnson (NYSE:JNJ) announced the European launch of its Shockwave Javelin Peripheral IVL Catheter, which is a groundbreaking platform to treat peripheral artery ...